# EDGAR Filing Document

**Accession Number:** 0001794783
**File Stem:** 0001794783-26-000027
**Filing Date:** 2026-5
**Character Count:** 62091
**Document Hash:** b07f82c05c19d8baa458f24913d003ab
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001794783-26-000027.hdr.sgml**: 20260505

**ACCESSION NUMBER**: 0001794783-26-000027

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 27

**CONFORMED PERIOD OF REPORT**: 20260505

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260505

**DATE AS OF CHANGE**: 20260505

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SelectQuote, Inc.
- **CENTRAL INDEX KEY:** 0001794783
- **STANDARD INDUSTRIAL CLASSIFICATION:** INSURANCE AGENTS BROKERS & SERVICES [6411]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 943339273
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39295
- **FILM NUMBER:** 26940456

**BUSINESS ADDRESS:**
- **STREET 1:** 6800 WEST 115TH STREET
- **STREET 2:** SUITE 2511
- **CITY:** OVERLAND PARK
- **STATE:** KS
- **ZIP:** 66211
- **BUSINESS PHONE:** 9132741994

**MAIL ADDRESS:**
- **STREET 1:** 6800 WEST 115TH STREET
- **STREET 2:** SUITE 2511
- **CITY:** OVERLAND PARK
- **STATE:** KS
- **ZIP:** 66211

?xml version='1.0' encoding='ASCII'? slqt-20260505

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**_______________________________________**

**FORM 8-K**

**_______________________________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 5, 2026**

_____________________________________

**SELECTQUOTE, INC.**

**(Exact name of registrant as specified in its charter)**

_____________________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39295** | **94-3339273** |
| (State or other jurisdiction of incorporation)  | (Commission File Number) | (I.R.S. Employer Identification No.)  |
| **6800 West 115th Street, Suite 2511** | **6800 West 115th Street, Suite 2511** | **6800 West 115th Street, Suite 2511** |
| **Overland Park, Kansas 66211** | **Overland Park, Kansas 66211** | **Overland Park, Kansas 66211** |
| (Address of principal executive offices) (Zip code) | (Address of principal executive offices) (Zip code) | (Address of principal executive offices) (Zip code) |
| **(913) 599-9225** | **(913) 599-9225** | **(913) 599-9225** |
| (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) |
| **No change since last report** | **No change since last report** | **No change since last report** |
| (Former Name or Address, If Changed Since Last Report) | (Former Name or Address, If Changed Since Last Report) | (Former Name or Address, If Changed Since Last Report) |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| Common Stock, $0.01 par value | SLQT | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02&nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition.**

On May 5, 2026, SelectQuote, Inc. reported its financial results for the third quarter ended March 31, 2026. Copies of the related press release and investor presentation are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.

These exhibits are being furnished pursuant to Item 2.02, and the information contained therein shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall either of them be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| <u>Exhibit No.</u> | <u>Description of Exhibit</u> |
| <u>[99.1](selectquoteincmarch312026pr.htm)</u> | Press Release |
| <u>[99.2](selectquoteincmarch31202.htm)</u> | Investor Presentation |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**SELECTQUOTE, INC.**

---

| | |
|:---|:---|
| Date: May 5, 2026 | By: /s/ Ryan M. Clement |
|  | Name: Ryan M. Clement |
|  | Title: Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**SelectQuote, Inc. Reports Third Quarter of Fiscal Year 2026 Results**

**Third Quarter of Fiscal Year 2026 – Consolidated Earnings Highlights**

• Revenue of $430.9 million

• Net income of $40.2 million

• Adjusted EBITDA\* of $44.6 million

**Fiscal Year 2026 Guidance Ranges:**

• Revenue expected in a range of $1.61 billion to $1.71 billion

• Adjusted EBITDA\* expected in a range of $90 million to $100 million

**Third Quarter Fiscal Year 2026 – Segment Highlights**

Senior

• Revenue of $182.9 million

• Adjusted EBITDA of $58.6 million

• Approved Medicare Advantage policies of 175,557

Healthcare Services

• Revenue of $199.4 million

• Adjusted EBITDA of $5.3 million

• 116,616 SelectRx members

Life

• Revenue of $47.9 million

• Adjusted EBITDA of $6.1 million

OVERLAND PARK, Kan., May 5, 2026--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT) reported consolidated revenue for the third quarter of fiscal year 2026 of $430.9 million compared to consolidated revenue for the third quarter of fiscal year 2025 of $408.2 million. Consolidated net income for the third quarter of fiscal year 2026 was $40.2 million compared to consolidated net income for the third quarter of fiscal year 2025 of $26.0 million. Finally, consolidated Adjusted EBITDA\* for the third quarter of fiscal year 2026 was $44.6 million compared to consolidated Adjusted EBITDA\* for the third quarter of fiscal year 2025 of $37.7 million.

SelectQuote Chief Executive Officer Tim Danker remarked, "SelectQuote delivered consistent profit and cash flow for another quarter, despite market shifts for both Medicare Advantage and prescription drugs. We reaffirm our financial outlook for fiscal 2026 driven by operating execution by our agents and continued leverage of our information and technology advantages. Revenue to customer acquisition cost of 6.7X represented a high water mark for the company, and more importantly, signals the value our differentiated healthcare service model provides to policyholders and prescription drug customers."

Mr. Danker continued, "Our goal to drive reliable and consistent profit, and cash flow growth remains priority number one. We believe the improvement to our capital structure to date, combined with the continued maturation of our SelectRx business, positions SelectQuote to materially expand cash flow in the years ahead. We continue to grow our receivables balance, which now stands at nearly $1 billion and grew by nearly $50 million over the past year, including a $14 million positive change in estimate reflective of the durability and dependability of these future cash flows."

*\* See "Non-GAAP Financial Measures" below.*

** <br> 1

------

**Segment Results**

We currently have three reportable segments: 1) Senior, 2) Healthcare Services and 3) Life. The performance measures of the segments include total revenue and adjusted EBITDA. Costs of commissions and other services revenue, cost of goods sold-pharmacy revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect costs of revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses are allocated to each segment based on varying metrics such as headcount.

**<u>Senior</u>**

**Financial Results**

The following table provides the financial results for the Senior segment for the periods presented:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | **Nine Months Ended March 31,** | **Nine Months Ended March 31,** | |
| *(in thousands)* | **2026** | **2025** | **% Change** | **2026** | **2025** | **% Change** |
| Revenue | $182890 | $169442 | 8% | $503426 | $517930 | (3)% |
| Adjusted EBITDA | 58642 | 45701 | 28% | 140057 | 153949 | (9)% |
| Adjusted EBITDA Margin | 32% | 27% |  | 28% | 30% |  |

---

**Operating Metrics**

***Submitted Policies***

Submitted policies are counted when an individual completes an application with our licensed agent and provides authorization to the agent to submit the application to the insurance carrier partner. The applicant may have additional actions to take before the application will be reviewed by the insurance carrier.

The following table shows the number of submitted policies for the periods presented:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | **Nine Months Ended March 31,** | **Nine Months Ended March 31,** | |
| | **2026** | **2025** | **% Change** | **2026** | **2025** | **% Change** |
| Medicare Advantage | 196970 | 201817 | (2)% | 553286 | 588872 | (6)% |
| All other <sup>(1)</sup> | 24912 | 22858 | 9% | 71632 | 65975 | 9% |
| Total | 221882 | 224675 | (1)% | 624918 | 654847 | (5)% |

---

(1) Represents the submitted policies for Medicare supplement, dental, vision and hearing, prescription drug plan and other.

***Approved Policies***

Approved policies represents the number of submitted policies that were approved by our insurance carrier partners for the identified product during the indicated period. Not all approved policies will go in force.

The following table shows the number of approved policies for the periods presented:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | **Nine Months Ended March 31,** | **Nine Months Ended March 31,** | |
| | **2026** | **2025** | **% Change** | **2026** | **2025** | **% Change** |
| Medicare Advantage | 175557 | 168001 | 4% | 495346 | 507530 | (2)% |
| All other <sup>(1)</sup> | 21152 | 17623 | 20% | 55330 | 50316 | 10% |
| Total | 196709 | 185624 | 6% | 550676 | 557846 | (1)% |

---

(1) Represents the approved policies for Medicare supplement, dental, vision and hearing, prescription drug plan and other.

------

***Lifetime Value of Commissions per Approved Policy***

Lifetime value of commissions per approved policy represents commissions estimated to be collected over the estimated life of an approved policy based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints. The lifetime value of commissions per approved policy is equal to the sum of the commission revenue due upon the initial sale of a policy, and when applicable, an estimate of future renewal commissions.

The following table shows the lifetime value of commissions per approved policy for the periods presented:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | **Nine Months Ended March 31,** | **Nine Months Ended March 31,** | |
| *(dollars per policy):* | **2026** | **2025** | **% Change** | **2026** | **2025** | **% Change** |
| Medicare Advantage | $904 | $915 | (1)% | $871 | $892 | (2)% |
| All other<sup>(1)</sup> | 81 | 151 | (46)% | 121 | 139 | (13)% |

---

(1) Represents the weighted average LTV per approved policy.

**<u>Healthcare Services</u>**

**Financial Results**

The following table provides the financial results for the Healthcare Services segment for the periods presented:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | **Nine Months Ended March 31,** | **Nine Months Ended March 31,** | |
| *(in thousands)* | **2026** | **2025** | **% Change** | **2026** | **2025** | **% Change** |
| Revenue | $199386 | $189569 | 5% | $651391 | $528677 | 23% |
| Adjusted EBITDA | 5278 | 6445 | (18)% | 13336 | 13534 | (1)% |
| Adjusted EBITDA Margin | 3% | 3% |  | 2% | 3% |  |

---

**Operating Metrics**

***Members***

The total number of SelectRx members represents the amount of active customers to which an order has been shipped and the prescriptions per day represents the total average prescriptions shipped per business day. These two metrics are the primary drivers of revenue for Healthcare Services.

The following table shows the total number of SelectRx members as of the periods presented:

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2025** |
| Total SelectRx Members | 116616 | 105523 |

---

The total number of SelectRx members increased by 11% as of March 31, 2026, compared to March 31, 2025, due to our strategy to grow SelectRx membership.

The following table shows the average prescriptions shipped per day for the periods presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Nine Months Ended March 31,** | **Nine Months Ended March 31,** |
| | **2026** | **2025** | **2026** | **2025** |
| Prescriptions Per Day | 33209 | 29015 | 32384 | 26942 |

---

------

**Combined Senior and Healthcare Services - Consumer Per Unit Economics**

Combined Senior and Healthcare Services consumer per unit economics represents total MA and MS commissions; other product commissions; other revenues, including revenues from Healthcare Services; and operating expenses associated with Senior and Healthcare Services, each shown per number of approved MA and MS policies over a given time period. Management assesses the business on a per-unit basis to help ensure that the revenue opportunity associated with a successful policy sale is attractive relative to the marketing acquisition cost. Because not all acquired leads result in a successful policy sale, all per-policy metrics are based on approved policies, which is the measure that triggers revenue recognition.

The MA and MS commission per MA/MS policy represents the LTV for policies sold in the period. Other commission per MA/MS policy represents the LTV for other products sold in the period, including DVH prescription drug plan, and other products, which management views as additional commission revenue on our agents' core function of MA/MS policy sales. Pharmacy revenue per MA/MS policy represents revenue from SelectRx, and other revenue per MA/MS policy represents revenue from Population Health, production bonuses, marketing development funds, lead generation revenue, and adjustments from the Company's reassessment of its cohorts' transaction prices. Total operating expenses per MA/MS policy represents all of the operating expenses within Senior and Healthcare Services. The revenue to customer acquisition cost ("CAC") multiple represents total revenue as a multiple of total marketing acquisition cost, which represents the direct costs of acquiring leads. These costs are included in marketing and advertising expense within the total operating expenses per MA/MS policy.

The following table shows combined Senior and Healthcare Services consumer per unit economics for the periods presented. Based on the seasonality of Senior and the fluctuations between quarters, we believe that the most relevant view of per unit economics is on a rolling 12-month basis. All per MA/MS policy metrics below are based on the sum of approved MA/MS policies, as both products have similar commission profiles.

---

| | | |
|:---|:---|:---|
| | **Twelve Months Ended March 31,** | **Twelve Months Ended March 31,** |
| *(dollars per approved policy):* | **2026** | **2025** |
| MA and MS approved policies | 582951 | 616379 |
| MA and MS commission per MA / MS policy | $868 | $885 |
| Other commission per MA/MS policy | 11 | 13 |
| Pharmacy revenue per MA/MS policy | 1461 | 1063 |
| Other revenue per MA/MS policy | 150 | 103 |
| Total revenue per MA / MS policy | 2490 | 2064 |
| Total operating expenses per MA / MS policy | (2193) | (1794) |
| Adjusted EBITDA per MA/MS policy | $297 | $270 |
| Adjusted EBITDA Margin per MA/MS policy | 12% | 13% |
| Revenue / CAC multiple | 6.7X | 5.8X |

---

Total revenue per MA/MS policy increased 21% for the twelve months ended March 31, 2026, compared to the twelve months ended March 31, 2025, primarily due to the increase in pharmacy revenue. Total operating expenses per MA/MS policy increased 22% for the twelve months ended March 31, 2026, compared to the twelve months ended March 31, 2025, driven by an increase in cost of goods sold-pharmacy revenue for Healthcare Services due to the growth of the business.

**<u>Life</u>**

**Financial Results**

The following table provides the financial results for the Life segment for the periods presented:

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | **Nine Months Ended March 31,** | **Nine Months Ended March 31,** | |
| *(in thousands)* | **2026** | **2025** | **% Change** | **2026** | **2025** | **% Change** |
| Revenue | $47896 | $45842 | 4% | $138166 | $124993 | 11% |
| Adjusted EBITDA | 6084 | 6364 | (4)% | 17236 | 19747 | (13)% |
| Adjusted EBITDA Margin | 13% | 14% |  | 13% | 16% |  |

---

**Operating Metrics**

Life premium represents the total premium value for all policies that were approved by the relevant insurance carrier partner and for which the policy document was sent to the policyholder and payment information was received by the relevant insurance carrier partner during the indicated period. Because our commissions are earned based on a percentage of total premium, total premium volume for a given period is the key driver of revenue for our Life segment.

The following table shows term and final expense premiums for the periods presented:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | **Nine Months Ended March 31,** | **Nine Months Ended March 31,** | |
| *(in thousands)* | **2026** | **2025** | **% Change** | **2026** | **2025** | **% Change** |
| Term Premiums | $19123 | $18930 | 1% | $56079 | $51459 | 9% |
| Final Expense Premiums | 27287 | 27681 | (1)% | 84072 | 74292 | 13% |
| Total | $46410 | $46611 | —% | $140151 | $125751 | 11% |

---

**Earnings Conference Call**

SelectQuote, Inc. will host a conference call with the investment community on May 5, 2026 beginning at 8:30 a.m. ET. To register for this conference call, please use this link: https://events.q4inc.com/analyst/775360431?pwd=VqmW7XWK. After registering, a confirmation will be sent via email, including dial-in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call we suggest registering at least 10 minutes before the start of the call. The event will also be webcasted live via our investor relations website https://ir.selectquote.com/investor-home/default.aspx.

**Non-GAAP Financial Measures**

*This release includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this release Adjusted EBITDA, which, when presented on a consolidated basis, is a non-GAAP financial measure. This non-GAAP financial measure is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to any similarly titled measure presented by other companies. We define Adjusted EBITDA as net income plus interest expense, income taxes, depreciation and amortization, changes in fair value of warrant liabilities, loss on extinguishment of debt, and certain add-backs for non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. The most directly comparable GAAP measure is net income. We monitor and have presented in this release Adjusted EBITDA because it is a key measure used by our management and Board of Directors to understand and evaluate our operating performance, establish budgets, and develop operational goals for managing our business. In particular, we believe that excluding the impact of these expenses in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance.*

*A reconciliation of the differences between Adjusted EBITDA and its most directly comparable GAAP measure, net income, is presented below on page 15. The Company is unable to provide a quantitative reconciliation of forward-looking Adjusted EBITDA to its most directly comparable GAAP measure without unreasonable effort because it is not possible to predict certain information included in the calculation of such GAAP measure, including the fair value of outstanding warrants to purchase shares of the Company's common stock. The unavailable information could have a significant impact on the Company's GAAP financial results.*

------

**Forward Looking Statements** 

*This release contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as "may," "should," "could," "predict," "potential," "believe," "will likely result," "expect," "continue," "will," "anticipate," "seek," "estimate," "intend," "plan," "projection," "would" and "outlook," or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts, and are based on current expectations, estimates and projections about our industry, management's beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements. There are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: our reliance on a limited number of insurance carrier partners and any potential termination of those relationships or failure to develop new relationships; existing and future laws and regulations affecting the health insurance market; changes in health insurance products offered by our insurance carrier partners and the health insurance market generally; insurance carriers offering products and services directly to consumers; changes to commissions paid by insurance carriers and underwriting practices; competition with brokers, exclusively online brokers and carriers who opt to sell policies directly to consumers; competition from government-run health insurance exchanges; developments in the U.S. health insurance system; our dependence on revenue from carriers in our senior segment and downturns in the senior health as well as life, automotive and home insurance industries; our ability to develop new offerings and penetrate new vertical markets; risks from third-party products; failure to enroll individuals during the Medicare annual enrollment period; our ability to attract, integrate and retain qualified personnel; our dependence on lead providers and ability to compete for leads; failure to obtain and/or convert sales leads to actual sales of insurance policies; access to data from consumers and insurance carriers; accuracy of information provided from and to consumers during the insurance shopping process; cost-effective advertisement through internet search engines; ability to contact consumers and market products by telephone; global economic conditions, including inflation; disruption to operations as a result of future acquisitions; significant estimates and assumptions in the preparation of our financial statements; impairment of goodwill; potential litigation and other legal proceedings or inquiries; our existing and future indebtedness; our ability to maintain compliance with our debt covenants; access to additional capital; our ability to regain and maintain compliance with NYSE listing standards; failure to protect our intellectual property and our brand; fluctuations in our financial results caused by seasonality; accuracy and timeliness of commissions reports from insurance carriers; timing of insurance carriers' approval and payment practices; factors that impact our estimate of the constrained lifetime value of commissions per policyholder; changes in accounting rules, tax legislation and other legislation; disruptions or failures of our technological infrastructure and platform; failure to maintain relationships with third-party service providers; cybersecurity breaches or other attacks involving our systems or those of our insurance carrier partners or third-party service providers; our ability to protect consumer information and other data; failure to market and sell Medicare plans effectively or in compliance with laws; and other factors related to our pharmacy business, including manufacturing or supply chain disruptions, access to and demand for prescription drugs, changes in reimbursement rates under our contracts with pharmacy benefit managers, and regulatory changes or other industry developments that may affect our pharmacy operations. For a further discussion of these and other risk factors that could impact our future results and performance, see the section entitled "Risk Factors" in the most recent Annual Report on Form 10-K (the "Annual Report") and subsequent periodic reports filed by us with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.*

**About SelectQuote:**

Founded in 1985, SelectQuote (NYSE: SLQT) pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies, allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote's success: a strong force of highly-trained and skilled

------

agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads. Today, the Company operates an ecosystem offering high touchpoints for consumers across insurance, pharmacy, and virtual care.

With an ecosystem offering engagement points for consumers across insurance, Medicare, pharmacy, and value-based care, the company now has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, SelectPatient Management, a provider of chronic care management services, and Healthcare Select which proactively connects consumers with a wide breadth of healthcare services supporting their needs.

Investor Relations:

Sloan Bohlen

877-678-4083

investorrelations@selectquote.com

Media:

Matt Gunter

913-286-4931

matt.gunter@selectquote.com

Source: SelectQuote, Inc.

------

**SELECTQUOTE, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(Unaudited)**

**(In thousands)**

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **June 30, 2025** |
| **ASSETS** | | |
| CURRENT ASSETS: |  |  |
| &nbsp;&nbsp;Cash, cash equivalents, and restricted cash | $35211 | $35733 |
| &nbsp;&nbsp;Accounts receivable, net of allowances of $9.2 million and $11.8 million, respectively | 234291 | 151388 |
| &nbsp;&nbsp;Commissions receivable-current | 76836 | 132077 |
| &nbsp;&nbsp;Other current assets | 20900 | 21844 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 367238 | 341042 |
| COMMISSIONS RECEIVABLE—Net | 882693 | 818751 |
| PROPERTY AND EQUIPMENT—Net | 13247 | 14577 |
| SOFTWARE—Net | 16953 | 15060 |
| OPERATING LEASE RIGHT-OF-USE ASSETS | 21566 | 24635 |
| INTANGIBLE ASSETS—Net | 1120 | 1973 |
| GOODWILL | 29438 | 29438 |
| OTHER ASSETS | 2455 | 3880 |
| TOTAL ASSETS | $1334710 | $1249356 |
| **LIABILITIES, PREFERRED STOCK, AND SHAREHOLDERS' EQUITY** |  |  |
| CURRENT LIABILITIES: |  |  |
| &nbsp;&nbsp;Accounts payable | $103205 | $59205 |
| &nbsp;&nbsp;Accrued expenses | 24092 | 13856 |
| &nbsp;&nbsp;Accrued compensation and benefits | 68646 | 58788 |
| &nbsp;&nbsp;Operating lease liabilities—current | 4665 | 4820 |
| &nbsp;&nbsp;Current portion of long-term debt | 22457 | 68523 |
| &nbsp;&nbsp;Other current liabilities | 8035 | 7718 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 231100 | 212910 |
| LONG-TERM DEBT, NET—less current portion | 353326 | 316589 |
| DEFERRED INCOME TAXES | 45211 | 37872 |
| OPERATING LEASE LIABILITIES | 22678 | 25982 |
| OTHER LIABILITIES | 18904 | 80485 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 671219 | 673838 |

---

------

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **June 30, 2025** |
| COMMITMENTS AND CONTINGENCIES |  |  |
| PREFERRED STOCK: |  |  |
| Senior Non-Convertible Preferred Stock, $0.01 par value, 350,000 shares issued and outstanding as of March 31, 2026 and June 30, 2025, respectively, current liquidation preference of $408.4 million and $367.1 million as of March 31, 2026 and June 30, 2025. | 278757 | 224374 |
| SHAREHOLDERS' EQUITY: |  |  |
| &nbsp;&nbsp;Common stock, $0.01 par value | 1763 | 1728 |
| &nbsp;&nbsp;Additional paid-in capital | 526129 | 571605 |
| &nbsp;&nbsp;Accumulated deficit | (143158) | (222189) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total shareholders' equity | 384734 | 351144 |
| TOTAL LIABILITIES, PREFERRED STOCK, AND SHAREHOLDERS' EQUITY | $1334710 | $1249356 |

---

------

**SELECTQUOTE, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**

**(Unaudited)**

**(In thousands)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Nine Months Ended March 31,** | **Nine Months Ended March 31,** |
| | **2026** | **2025** | **2026** | **2025** |
| REVENUE: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Commissions and other services | $235663 | $222889 | $655823 | $663338 |
| &nbsp;&nbsp;&nbsp;&nbsp;Pharmacy | 195270 | 185271 | 641023 | 518154 |
| Total revenue | 430933 | 408160 | 1296846 | 1181492 |
| OPERATING COSTS AND EXPENSES: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of commissions and other services revenue | 83268 | 79412 | 255403 | 246283 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of goods sold—pharmacy revenue | 171289 | 162304 | 569262 | 448029 |
| &nbsp;&nbsp;&nbsp;&nbsp;Marketing and advertising | 92481 | 92733 | 259456 | 254222 |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general, and administrative | 38188 | 41685 | 112948 | 122850 |
| &nbsp;&nbsp;&nbsp;&nbsp;Technical development | 9777 | 9967 | 29283 | 29086 |
| Total operating costs and expenses | 395003 | 386101 | 1226352 | 1100470 |
| INCOME FROM OPERATIONS | 35930 | 22059 | 70494 | 81022 |
| INTEREST EXPENSE, NET | (10602) | (20407) | (34023) | (67160) |
| CHANGE IN FAIR VALUE OF WARRANTS | 27489 | 32986 | 61821 | 25344 |
| LOSS ON EXTINGUISHMENT OF DEBT | (8659) |  | (8659) |  |
| OTHER EXPENSE, NET | (34) | (37) | (216) | (70) |
| INCOME BEFORE INCOME TAX EXPENSE | 44124 | 34601 | 89417 | 39136 |
| INCOME TAX EXPENSE | 3927 | 8579 | 10386 | 4424 |
| NET INCOME | $40197 | $26022 | $79031 | $34712 |
| &nbsp;&nbsp;&nbsp;&nbsp;Senior Non-Convertible Preferred Stock accumulated dividends and accretion | (18775) | (5787) | (54382) | (5787) |
| NET INCOME ATTRIBUTABLE TO COMMON SHAREHOLDERS | $21422 | $20235 | $24649 | $28925 |
| NET INCOME ATTRIBUTABLE TO COMMON SHAREHOLDERS PER SHARE: |  |  |  |  |
| &nbsp;&nbsp;Basic | $0.11 | $0.11 | $0.13 | $0.17 |
| &nbsp;&nbsp;Diluted | $0.11 | $0.03 | $0.11 | $0.13 |
| WEIGHTED-AVERAGE COMMON STOCK OUTSTANDING USED IN PER SHARE AMOUNTS: |  |  |  |  |
| &nbsp;&nbsp;Basic | 189455 | 178156 | 187614 | 173462 |
| &nbsp;&nbsp;Diluted | 190481 | 186639 | 190647 | 178895 |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Nine Months Ended March 31,** | **Nine Months Ended March 31,** |
| | **2026** | **2025** | **2026** | **2025** |
| OTHER COMPREHENSIVE LOSS, NET OF TAX: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized loss, net of related tax benefit for the three and nine months ended March 31, 2026, and 2025, of $0.0 million and $0.1 million |  |  |  | (432) |
| &nbsp;&nbsp;&nbsp;&nbsp;Amount reclassified into earnings, net of related tax benefit for the three months ended March 31, 2026, and 2025, of $0.0 million, and $0.0 million and for the nine months ended March 31, 2026, and 2025, of $0.0 million and $1.3 million. |  |  |  | (3680) |
| OTHER COMPREHENSIVE LOSS |  |  |  | (4112) |
| COMPREHENSIVE INCOME | $40197 | $26022 | $79031 | $30600 |

---

------

**SELECTQUOTE, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(Unaudited)**

**(In thousands)**

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended March 31,** | **Nine Months Ended March 31,** |
| | **2026** | **2025** |
| CASH FLOWS FROM OPERATING ACTIVITIES: |  |  |
| &nbsp;&nbsp;&nbsp;Net income | $79031 | $34712 |
| &nbsp;&nbsp;Adjustments to reconcile net income to net cash, cash equivalents, and restricted cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 13007 | 15584 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on disposal of property, equipment, and software |  | 160 |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment of equity-method investment | 1000 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on extinguishment of debt | 8659 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation expense | 11480 | 13505 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | 7340 | 4424 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt issuance costs and debt discount | 3343 | 3880 |
| &nbsp;&nbsp;&nbsp;&nbsp;Write-off of debt issuance costs |  | 93 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued interest payable in kind |  | 13301 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of warrants | (61821) | (25344) |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-cash lease expense | 3070 | 2849 |
| &nbsp;&nbsp;&nbsp;&nbsp;Bad debt expense |  | 4203 |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | (82903) | (39047) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commissions receivable | (8702) | (33765) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | 1261 | (343) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | 53583 | 41163 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | (3459) | (3574) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | 10315 | (5985) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | 35204 | 25816 |
| CASH FLOWS FROM INVESTING ACTIVITIES: |  |  |
| &nbsp;&nbsp;&nbsp;Purchases of property and equipment | (3093) | (1690) |
| &nbsp;&nbsp;&nbsp;Purchases of software and capitalized software development costs | (8490) | (6513) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (11583) | (8203) |
| CASH FLOWS FROM FINANCING ACTIVITIES: |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from revolving credit facility | 270000 | 166900 |
| &nbsp;&nbsp;&nbsp;Payments on revolving credit facility | (270000) | (166900) |
| &nbsp;&nbsp;Net proceeds from Term Loan | 315234 |  |
| &nbsp;&nbsp;&nbsp;Payments on Term Loans | (314000) | (384644) |
| &nbsp;&nbsp;&nbsp;Proceeds from ABS Notes |  | 99095 |
| &nbsp;&nbsp;&nbsp;Payments on ABS Notes | (15016) | (11723) |
| &nbsp;&nbsp;&nbsp;Payments on other debt | (380) | (202) |
| &nbsp;&nbsp;&nbsp;Proceeds from common stock options exercised and employee stock purchase plan |  | 112 |
| &nbsp;&nbsp;&nbsp;Proceeds from issuance of Senior Non-Convertible Preferred Stock |  | 337855 |
| &nbsp;&nbsp;&nbsp;Senior Non-Convertible Preferred Stock issuance costs |  | (7076) |
| &nbsp;&nbsp;&nbsp;Payments of tax withholdings related to net share settlement of equity awards | (2539) | (5019) |
| &nbsp;&nbsp;Payments of debt issuance costs | (7730) | (2479) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash (used in) provided by financing activities | (24431) | 25919 |
| NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | (810) | 43532 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH —Beginning of period | 37066 | 42690 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH —End of period | $36256 | $86222 |

---

------

**SELECTQUOTE, INC. AND SUBSIDIARIES**

**Reconciliation by Segment of Adjusted EBITDA to Income before income tax expense**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** |
| *(in thousands)* | **Senior** | **Healthcare Services** | **Life** | **Total** |
| Total revenue from reportable segments | $182890 | $199386 | $47896 | $430172 |
| Less: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Cost of commissions and other services revenue | (54596) | (6976) | (18465) |  |
| &nbsp;&nbsp;&nbsp;Cost of goods sold - pharmacy revenue |  | (169814) |  |  |
| &nbsp;&nbsp;&nbsp;Marketing expense | (69060) | (1686) | (23131) |  |
| &nbsp;&nbsp;&nbsp;Technical development |  | (318) |  |  |
| &nbsp;&nbsp;&nbsp;Selling, general, and administrative | (592) | (15314) | (216) |  |
| **Adjusted Segment EBITDA** | $58642 | $5278 | $6084 | $70004 |
| *Reconciliation of total segment Adjusted EBITDA* |  |  |  |  |
| All other Adjusted EBITDA |  |  |  | 1376 |
| Corporate |  |  |  | (26790) |
| Share-based compensation expense |  |  |  | (3678) |
| Transaction costs |  |  |  | (631) |
| Depreciation and amortization |  |  |  | (4385) |
| Loss on extinguishment of debt |  |  |  | (8659) |
| Change in fair value of warrants |  |  |  | 27489 |
| Interest expense, net |  |  |  | (10602) |
| Income before income tax expense |  |  |  | $44124 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** |
| *(in thousands)* | **Senior** | **Healthcare Services** | **Life** | **Total** |
| Total revenue from reportable segments | $169442 | $189569 | $45842 | $404853 |
| Less: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Cost of commissions and other services revenue | (53374) | (5816) | (17415) |  |
| &nbsp;&nbsp;&nbsp;Cost of goods sold - pharmacy revenue |  | (161026) |  |  |
| &nbsp;&nbsp;&nbsp;Marketing expense | (69808) | (1939) | (21789) |  |
| &nbsp;&nbsp;&nbsp;Technical development |  | (491) |  |  |
| &nbsp;&nbsp;&nbsp;Selling, general, and administrative | (559) | (13852) | (274) |  |
| **Adjusted Segment EBITDA** | $45701 | $6445 | $6364 | $58510 |
| *Reconciliation of total segment Adjusted EBITDA* |  |  |  |  |
| All other Adjusted EBITDA |  |  |  | 3549 |
| Corporate |  |  |  | (24336) |
| Share-based compensation expense |  |  |  | (4960) |
| Transaction costs |  |  |  | (5813) |
| Depreciation and amortization |  |  |  | (4925) |
| Loss on disposal of property, equipment, and software, net |  |  |  | (3) |
| Change in fair value of warrants |  |  |  | 32986 |
| Interest expense, net |  |  |  | (20407) |
| Income before income tax expense |  |  |  | $34601 |

---

------

**SELECTQUOTE, INC. AND SUBSIDIARIES**

**Reconciliation by Segment of Adjusted EBITDA to Income before income tax expense**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Nine Months Ended March 31, 2026** | **Nine Months Ended March 31, 2026** | **Nine Months Ended March 31, 2026** | **Nine Months Ended March 31, 2026** |
| *(in thousands)* | **Senior** | **Healthcare Services** | **Life** | **Total** |
| Total revenue from reportable segments | $503426 | $651391 | $138166 | $1292983 |
| Less: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Cost of commissions and other services revenue | (170884) | (21635) | (53848) |  |
| &nbsp;&nbsp;&nbsp;Cost of goods sold - pharmacy revenue |  | (564995) |  |  |
| &nbsp;&nbsp;&nbsp;Marketing expense | (190746) | (6309) | (66267) |  |
| &nbsp;&nbsp;&nbsp;Technical development |  | (1068) |  |  |
| &nbsp;&nbsp;&nbsp;Selling, general, and administrative | (1739) | (44048) | (815) |  |
| **Adjusted Segment EBITDA** | $140057 | $13336 | $17236 | $170629 |
| *Reconciliation of total segment Adjusted EBITDA* |  |  |  |  |
| All other Adjusted EBITDA |  |  |  | 5366 |
| Corporate |  |  |  | (78752) |
| Share-based compensation expense |  |  |  | (11480) |
| Transaction costs |  |  |  | (1478) |
| Depreciation and amortization |  |  |  | (13007) |
| Impairment of equity-method investment |  |  |  | (1000) |
| Loss on extinguishment of debt |  |  |  | (8659) |
| Change in fair value of warrants |  |  |  | 61821 |
| Interest expense, net |  |  |  | (34023) |
| Income before income tax expense |  |  |  | $89417 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Nine Months Ended March 31, 2025** | **Nine Months Ended March 31, 2025** | **Nine Months Ended March 31, 2025** | **Nine Months Ended March 31, 2025** |
| *(in thousands)* | **Senior** | **Healthcare Services** | **Life** | **Total** |
| Total revenue from reportable segments | $517930 | $528677 | $124993 | $1171600 |
| Less: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Cost of commissions and other services revenue | (169543) | (19627) | (47028) |  |
| &nbsp;&nbsp;&nbsp;Cost of goods sold - pharmacy revenue |  | (444401) |  |  |
| &nbsp;&nbsp;&nbsp;Marketing expense | (192583) | (6088) | (57456) |  |
| &nbsp;&nbsp;&nbsp;Technical development |  | (1691) |  |  |
| &nbsp;&nbsp;&nbsp;Selling, general, and administrative | (1855) | (43336) | (762) |  |
| **Adjusted Segment EBITDA** | $153949 | $13534 | $19747 | $187230 |
| *Reconciliation of total segment Adjusted EBITDA* |  |  |  |  |
| All other Adjusted EBITDA |  |  |  | 9645 |
| Corporate |  |  |  | (73316) |
| Share-based compensation expense |  |  |  | (13505) |
| Transaction costs |  |  |  | (13358) |
| Depreciation and amortization |  |  |  | (15584) |
| Loss on disposal of property, equipment, and software, net |  |  |  | (160) |
| Change in fair value of warrants |  |  |  | 25344 |
| Interest expense, net |  |  |  | (67160) |
| Income before income tax expense |  |  |  | $39136 |

---

------

**RECONCILIATION OF NON-GAAP MEASURE**

**SELECTQUOTE, INC. AND SUBSIDIARIES**

**Reconciliation of Net income to Adjusted EBITDA**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Nine Months Ended March 31,** | **Nine Months Ended March 31,** |
| *(in thousands)* | **2026** | **2025** | **2026** | **2025** |
| Net income | $40197 | $26022 | $79031 | $34712 |
| &nbsp;&nbsp;&nbsp;Share-based compensation expense | 3678 | 4960 | 11480 | 13505 |
| &nbsp;&nbsp;&nbsp;Transaction costs | 631 | 5813 | 1478 | 13358 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 4385 | 4925 | 13007 | 15584 |
| &nbsp;&nbsp;&nbsp;Loss on disposal of property, equipment, and software, net |  | 3 |  | 160 |
| &nbsp;&nbsp;Impairment of equity-method investment |  |  | 1000 |  |
| &nbsp;&nbsp;Loss on extinguishment of debt | 8659 |  | 8659 |  |
| &nbsp;&nbsp;&nbsp;Change in fair value of warrants | (27489) | (32986) | (61821) | (25344) |
| &nbsp;&nbsp;&nbsp;Interest expense, net | 10602 | 20407 | 34023 | 67160 |
| &nbsp;&nbsp;&nbsp;Income tax expense | 3927 | 8579 | 10386 | 4424 |
| Adjusted EBITDA | $44590 | $37723 | $97243 | $123559 |

---

## Exhibit 99.2

![](selectquoteincmarch31202001.jpg)

\| We shop. You save. 3rd Quarter Fiscal 2026 Earnings Presentation May 5, 2026 Exhibit 99.2

------

![](selectquoteincmarch31202002.jpg)

\| We shop. You save. Forward-Looking Statements This presentation contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as "may," "should," "could," "predict," "potential," "believe," "will likely result," "expect," "continue," "will," "anticipate," "seek," "estimate," "intend," "plan," "projection," "would" and "outlook," or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts and are based on current expectations, estimates and projections about our industry, management's beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements. There are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: our reliance on a limited number of insurance carrier partners and any potential termination of those relationships or failure to develop new relationships; existing and future laws and regulations affecting the health insurance market; changes in health insurance products offered by our insurance carrier partners and the health insurance market generally; insurance carriers offering products and services directly to consumers; changes to commissions paid by insurance carriers and underwriting practices; competition with brokers, exclusively online brokers and carriers who opt to sell policies directly to consumers; competition from government-run health insurance exchanges; developments in the U.S. health insurance system; our dependence on revenue from carriers in our senior segment and downturns in the senior health as well as life, automotive and home insurance industries; our ability to develop new offerings and penetrate new vertical markets; risks from third-party products; failure to enroll individuals during the Medicare annual enrollment period; our ability to attract, integrate and retain qualified personnel; our dependence on lead providers and ability to compete for leads; failure to obtain and/or convert sales leads to actual sales of insurance policies; access to data from consumers and insurance carriers; accuracy of information provided from and to consumers during the insurance shopping process; cost- effective advertisement through internet search engines; ability to contact consumers and market products by telephone; global economic conditions, including inflation; disruption to operations as a result of future acquisitions; significant estimates and assumptions in the preparation of our financial statements; impairment of goodwill; potential litigation and other legal proceedings or inquiries; our existing and future indebtedness; our ability to maintain compliance with our debt covenants; access to additional capital; our ability to regain and maintain compliance with NYSE listing standards; failure to protect our intellectual property and our brand; fluctuations in our financial results caused by seasonality; accuracy and timeliness of commissions reports from insurance carriers; timing of insurance carriers' approval and payment practices; factors that impact our estimate of the constrained lifetime value of commissions per policyholder; changes in accounting rules, tax legislation and other legislation; disruptions or failures of our technological infrastructure and platform; failure to maintain relationships with third-party service providers; cybersecurity breaches or other attacks involving our systems or those of our insurance carrier partners or third-party service providers; our ability to protect consumer information and other data; failure to market and sell Medicare plans effectively or in compliance with laws; and other factors related to our pharmacy business, including manufacturing or supply chain disruptions, access to and demand for prescription drugs, changes in reimbursement rates under our contracts with pharmacy benefit managers, and regulatory changes or other industry developments that may affect our pharmacy operations. For a further discussion of these and other risk factors that could impact our future results and performance, see the section entitled "Risk Factors" in the most recent Annual Report on Form 10-K (the "Annual Report") and subsequent periodic reports filed by us with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. No Offer or Solicitation; Further Information This presentation is for informational purposes only and is not an offer to sell with respect to any securities. This presentation should be read together with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the consolidated financial statements and the related notes thereto included in the Annual Report and subsequent quarterly reports. Non-GAAP Financial Measures This presentation includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this presentation Adjusted EBITDA, which, when presented on a consolidated basis, is a non-GAAP financial measure. This non-GAAP financial measure is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to any similarly titled measure presented by other companies. We define Adjusted EBITDA as net income (loss) plus interest expense, income taxes, depreciation and amortization, changes in fair value of warrant liabilities, loss on extinguishment of debt, and certain add-backs for non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. The most directly comparable GAAP measure for Adjusted EBITDA is net income (loss). We monitor and have presented in this presentation Adjusted EBITDA because it is a key measure used by our management and Board of Directors in understanding and evaluating our operating performance, establishing budgets, and developing operational goals for managing our business. In particular, we believe that excluding the impact of certain expenses in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance. For further discussion regarding this non-GAAP measure, please see today's press release. A reconciliation of the differences between Adjusted EBITDA and its most directly comparable GAAP financial measure, net income (loss), is set forth below on slide 11. The Company is unable to provide a quantitative reconciliation of forward-looking Adjusted EBITDA to its most directly comparable GAAP measure without unreasonable effort because it is not possible to predict certain items included in the calculation of such GAAP measure, including the fair value of outstanding warrants to purchase shares of the Company's common stock. The unavailable information could have a significant impact on the Company's GAAP financial results. Disclaimer 2

------

![](selectquoteincmarch31202003.jpg)

\| We shop. You save. 3Q Earnings Highlights 3 • Consolidated ◦ Revenue increased 6% and Adjusted EBITDA\* increased 18% year-over-year, driven by continued Healthcare Services growth and a strong Senior OEP • Senior ◦ Adjusted EBITDA increased 28% year-over-year to $59 million in 3Q, including a positive change in estimate of $14 million to commissions receivable ◦ Solid agent productivity and marketing efficiency yielded 32% Adjusted EBITDA margins ◦ Existing customer and new customer retention improved year-to-date in 2026 • Healthcare Services ◦ 3Q Adjusted EBITDA increased to $5 million as PBM reimbursement rates increased on January 1st ◦ Revenue grew 5% year-over-year to $199 million despite Inflation Reduction Act impacts • SelectQuote Local ◦ Leverages industry-leading marketing, technology, customer service, and carrier relationships to offer Senior and Life products through a franchising model with local sales and service \*See "Non-GAAP Financial Measures" section on slide 2

------

![](selectquoteincmarch31202004.jpg)

\| We shop. You save. 3Q24 3Q25 3Q26 3Q24 3Q25 3Q26 4.2x 5.8x 6.7x 3Q24 3Q25 3Q26 20k 29k 33k 3Q24 3Q25 3Q26 Prescriptions Per DayAgent Productivity† Revenue / CAC\*\* †Percentage change deltas are calculated relative to 3Q24 results. \*Represents total Senior division marketing expenses per approved Medicare Advantage and Medicare Supplement policy. Marketing Expense Per Policy\*† 1% 14% 4 \*\*The revenue to customer acquisition cost ("CAC") multiple represents total revenue as a multiple of total marketing acquisition costs for the Senior and Healthcare Services divisions, which represents the direct costs of acquiring leads. Senior Healthcare Services Execution Fuels Cash Flow Generation

------

![](selectquoteincmarch31202005.jpg)

\| We shop. You save. • Revenue growth driven by Healthcare Services, strong Senior OEP results, and a positive change in estimate • Adjusted EBITDA\* of $45 million increased 18% year-over-year • Robust 32% Senior Adjusted EBITDA margins, inclusive of $14 million change in estimate $408 $431 3Q25 3Q26 Consolidated Financial Summary \*See "Non-GAAP Financial Measures" section on slide 2 Commentary $38 $45 3Q25 3Q26 5 Revenue $MM Adjusted EBITDA\* $MM

------

![](selectquoteincmarch31202006.jpg)

\| We shop. You save. $169 $183 3Q25 3Q26 Revenue $MM Adjusted EBITDA $MM Senior Financial Summary Commentary $46 $59 3Q25 3Q26 27% 32% • Senior revenue of $183 million, up 8% year-over-year • Adjusted EBITDA increased year- over-year to $59 million • $14 million change in estimate to commissions receivable • Strong 32% Adjusted EBITDA margins 6

------

![](selectquoteincmarch31202007.jpg)

\| We shop. You save. SELECTRX Members 106 108 107 113 117 3Q25 4Q25 1Q26 2Q26 3Q26 0 20 40 60 80 100 120 140 Revenue & Adjusted EBITDA $MM $6 $12 $7 $1 $5 $190 $214 $221 $231 $199 3Q25 4Q25 1Q26 2Q26 3Q26 Healthcare Services KPIs REVENUE ADJUSTED EBITDA 7

------

![](selectquoteincmarch31202008.jpg)

\| We shop. You save. • Revenue increased 4% year-over- year driven by continued strong Final Expense performance • Adjusted EBITDA remained steady year-over-year in 3Q $6 $6 3Q25 3Q26 $46 $48 3Q25 3Q26 Life Financial Summary Adjusted EBITDA $MM Commentary Revenue $MM 8

------

![](selectquoteincmarch31202009.jpg)

\| We shop. You save. Reiterating FY26 Financial Guidance REVENUE $1.61B ADJUSTED EBITDA\* to $1.71B $90M to $100M \*See "Non-GAAP Financial Measures" above on slide 2. 9

------

![](selectquoteincmarch31202010.jpg)

\| We shop. You save. Supplemental Information 10

------

![](selectquoteincmarch31202011.jpg)

\| We shop. You save. Reconciliation of Non-GAAP Measure Reconciliation of Net Income to Adjusted EBITDA 11 3Q FY FY YTD (in thousands) 2026 2025 2026 2025 Net income $40,197 $26,022 $79,031 $34,712 Share-based compensation expense 3,678 4,960 11,480 13,505 Transaction costs 631 5,813 1,478 13,358 Depreciation and amortization 4,385 4,925 13,007 15,584 Loss on disposal of property, equipment, and software, net — 3 — 160 Impairment of equity-method investment — — 1,000 — Loss on extinguishment of debt 8,659 — 8,659 — Change in fair value of warrants (27,489) (32,986) (61,821) (25,344) Interest expense, net 10,602 20,407 34,023 67,160 Income tax expense 3,927 8,579 10,386 4,424 Adjusted EBITDA $44,590 $37,723 $97,243 $123,559

------

![](selectquoteincmarch31202012.jpg)

\| We shop. You save. 3Q FY 2026 (in thousands) Senior Healthcare Services Life Total Total revenue from reportable segments $182,890 $199,386 $47,896 $430,172 Less: Cost of commissions and other services revenue (54,596) (6,976) (18,465) Cost of goods sold - pharmacy revenue — (169,814) — Marketing expense (69,060) (1,686) (23,131) Technical development — (318) — Selling, general, and administrative (592) (15,314) (216) Adjusted Segment EBITDA $58,642 $5,278 $6,084 $70,004 Reconciliation of total segment Adjusted EBITDA All other Adjusted EBITDA 1,376 Corporate (26,790) Share-based compensation expense (3,678) Transaction costs (631) Depreciation and amortization (4,385) Loss on extinguishment of debt (8,659) Change in fair value of warrants 27,489 Interest expense, net (10,602) Income before income tax expense $44,124 Reconciliation by Segment of Adjusted EBITDA to Income before income tax expense 12

------

![](selectquoteincmarch31202013.jpg)

\| We shop. You save. 3Q FY 2025 (in thousands) Senior Healthcare Services Life Total Total revenue from reportable segments $169,442 $189,569 $45,842 $404,853 Less: Cost of commissions and other services revenue (53,374) (5,816) (17,415) Cost of goods sold - pharmacy revenue — (161,026) — Marketing expense (69,808) (1,939) (21,789) Technical development — (491) — Selling, general, and administrative (559) (13,852) (274) Adjusted Segment EBITDA $45,701 $6,445 $6,364 $58,510 Reconciliation of total segment Adjusted EBITDA All other Adjusted EBITDA 3,549 Corporate (24,336) Share-based compensation expense (4,960) Transaction costs (5,813) Depreciation and amortization (4,925) Loss on disposal of property, equipment, and software, net (3) Change in fair value of warrants 32,986 Interest expense, net (20,407) Income before income tax expense $34,601 Reconciliation by Segment of Adjusted EBITDA to Income before income tax expense 13

------

![](selectquoteincmarch31202014.jpg)

\| We shop. You save. SelectQuote Inc. 6800 West 115th Street Suite 2511 Overland Park, Kansas 66211 Phone: (877) 678-4086 Investor Relations investorrelations@selectquote.com 14

------